What neurological side effects have been reported with ivermectin in humans?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Ivermectin use in humans has been associated with a spectrum of neurological effects ranging from common, mild symptoms such as headache, dizziness and somnolence to rare, severe events including encephalopathy, stupor, seizures and coma; serious cases have most often occurred in specific contexts—high Loa loa microfilarial burden, genetic defects in the ABCB1/P‑glycoprotein transporter, or massive/intentional overdose [1] [2] [3]. Overall, large post‑marketing and pharmacovigilance reviews describe these severe neurological adverse events as uncommon relative to widespread safe use, but clustered in identifiable high‑risk settings [4] [5].
1. What neurologic symptoms are reported most often (the mild end of the spectrum)
Common nervous‑system complaints reported in clinical trials and pharmacovigilance include headache, dizziness/vertigo, somnolence, tremor and transient confusion or visual disturbance; these are repeatedly listed in drug safety summaries and systematic reviews as the routine neurologic adverse events after therapeutic doses [1] [6] [2].
2. The serious neurologic syndromes: encephalopathy, stupor, seizures and coma
Case series and database analyses document rare but serious presentations—encephalopathy with reduced consciousness, stupor, seizure activity and coma—most notably observed during mass ivermectin campaigns in areas co‑endemic for Loa loa, where high microfilarial loads temporally related to ivermectin dosing were linked to encephalopathic syndromes [3] [7] [8].
3. Why do severe reactions happen in some people? Mechanisms and genetic vulnerability
Two non‑exclusive mechanisms dominate the literature: first, neurologic deterioration after ivermectin in Africa has been correlated with very high Loa loa microfilaremia, suggesting parasite‑related inflammatory or microvascular processes after rapid killing [3] [5]; second, failure of the ABCB1/P‑glycoprotein blood‑brain efflux pump—whether from rare human nonsense mutations or pharmacologic overload—permits ivermectin to enter the CNS and act on GABA/glycine receptors, producing classical neurotoxic signs [9] [10] [11].
4. Overdose, misuse and the COVID‑19 era: shifting patterns and new reports
Reports of neurologic toxicity increased during the COVID‑19 pandemic because of non‑prescribed human use and ingestion of veterinary formulations; poison‑center series and case reports document confusion, decreased sensorium and hospitalizations from supratherapeutic exposure, underscoring that overdose can overwhelm protective transporters and cause CNS effects [12] [10] [2].
5. How common are severe neurologic events, and how should that be interpreted
Systematic pharmacovigilance work searching WHO VigiBase and regional case series finds dozens of serious neurologic incident reports but places them against millions of safe doses given worldwide, leading authors to characterize such events as rare overall while warning of clustering where co‑endemic infections or genetic vulnerabilities exist [5] [4] [8].
6. Conflicting interpretations, hidden agendas and clinical implications
Some researchers emphasize that ivermectin’s safety profile is well established for indicated parasitic uses and that most neurologic harms are context‑specific (Loa loa, ABCB1 defects, overdose), while others argue case series indicate risks beyond those settings—an interpretive tension visible in papers that both defend routine use and call for caution in non‑endemic or off‑label prescribing [4] [3]. Public controversy around ivermectin during the COVID‑19 pandemic introduced a policy and communications layer—expanded off‑label demand and veterinary product misuse inflated toxic‑exposure reports, a dynamic that can obscure the baseline risk seen in controlled, indicated use [12] [13]. Clinical takeaway from these sources: expect mostly mild neurological effects at therapeutic antiparasitic doses, but recognize rare severe syndromes tied to high Loa loa burden, ABCB1/P‑glycoprotein failure or overdose, and apply screening, dosing limits and vigilance accordingly [5] [9] [10].